Artwork

コンテンツは Pharma and BioTech News and BioTech News によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Pharma and BioTech News and BioTech News またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!

Pharma and Biotech Daily: Stay Informed, Stay Ahead

2:10
 
シェア
 

Manage episode 460120041 series 3478766
コンテンツは Pharma and BioTech News and BioTech News によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Pharma and BioTech News and BioTech News またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Galapagos is set to split into two entities by mid-2025, creating a new innovative medicines specialist and a cell therapy company. Novo has invested $4.6 billion to expand its deal with Valo, aiming to maintain leadership in the cardiometabolic space. Tenvie, supported by venture partners, will be focusing on developing brain-penetrant small molecules for neurological and metabolic diseases.The trend of licensing deals in the pharmaceutical industry is on the rise, with experts debating whether it is a sign of desperation or a crucial part of the biotech ecosystem. Roche is in the final stages of acquiring Poseida for up to $1.5 billion, while Cassava has had to lay off a third of its staff following a setback in an Alzheimer's drug trial. Major pharmaceutical companies are looking towards China for potential deal opportunities, despite regulatory uncertainty in the region. The FDA is considering setting a bar for weight-loss therapies as the obesity space continues to heat up. Looking ahead to 2025, there is a cautiously optimistic outlook for the biopharma industry, with predictions of increased M&A activity leading up to key events like the J.P. Morgan Healthcare Conference and important FDA decisions.As licensing deals become more common in the biotech industry, big pharma companies are exploring partnerships in China. The industry is gearing up for the J.P. Morgan Healthcare Conference with a sense of uncertainty after M&A activity did not meet expectations in 2024. Biospace's NextGen Class of 2025 features startups focusing on emerging trends in biopharma, attracting investments from major players.Companies like Roche, Merck, and Novo are making significant moves in the biopharma space, shaping the industry landscape. Job opportunities are available in various sectors, including positions like Chief of Staff and Senior Director in IT and Translational Neuroscience. Biospace is working on enhancing user experience by personalizing emails based on individual preferences.Thank you for tuning in to Pharma and Biotech Daily, where we bring you the latest updates and insights from the world of pharmaceuticals and biotechnology.
  continue reading

65 つのエピソード

Artwork
iconシェア
 
Manage episode 460120041 series 3478766
コンテンツは Pharma and BioTech News and BioTech News によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Pharma and BioTech News and BioTech News またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Galapagos is set to split into two entities by mid-2025, creating a new innovative medicines specialist and a cell therapy company. Novo has invested $4.6 billion to expand its deal with Valo, aiming to maintain leadership in the cardiometabolic space. Tenvie, supported by venture partners, will be focusing on developing brain-penetrant small molecules for neurological and metabolic diseases.The trend of licensing deals in the pharmaceutical industry is on the rise, with experts debating whether it is a sign of desperation or a crucial part of the biotech ecosystem. Roche is in the final stages of acquiring Poseida for up to $1.5 billion, while Cassava has had to lay off a third of its staff following a setback in an Alzheimer's drug trial. Major pharmaceutical companies are looking towards China for potential deal opportunities, despite regulatory uncertainty in the region. The FDA is considering setting a bar for weight-loss therapies as the obesity space continues to heat up. Looking ahead to 2025, there is a cautiously optimistic outlook for the biopharma industry, with predictions of increased M&A activity leading up to key events like the J.P. Morgan Healthcare Conference and important FDA decisions.As licensing deals become more common in the biotech industry, big pharma companies are exploring partnerships in China. The industry is gearing up for the J.P. Morgan Healthcare Conference with a sense of uncertainty after M&A activity did not meet expectations in 2024. Biospace's NextGen Class of 2025 features startups focusing on emerging trends in biopharma, attracting investments from major players.Companies like Roche, Merck, and Novo are making significant moves in the biopharma space, shaping the industry landscape. Job opportunities are available in various sectors, including positions like Chief of Staff and Senior Director in IT and Translational Neuroscience. Biospace is working on enhancing user experience by personalizing emails based on individual preferences.Thank you for tuning in to Pharma and Biotech Daily, where we bring you the latest updates and insights from the world of pharmaceuticals and biotechnology.
  continue reading

65 つのエピソード

すべてのエピソード

×
 
Loading …

プレーヤーFMへようこそ!

Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。

 

クイックリファレンスガイド

探検しながらこの番組を聞いてください
再生